Coprescribing of opioids and high-risk medications in the USA: a cross-sectional study with data from national ambulatory and emergency department settings

Kara Suvada, Anna Zimmer, Jesse Soodalter, Jimi S Malik, Dio Kavalieratos, Mohammed K Ali

ABSTRACT

Objective Describe trends in opioid plus high-risk medication coprescribing in the USA.

Design Analyses of serial, cross-sectional, nationally representative data of the National Ambulatory Medical Care Survey (NAMCS) over 2007–2016 and the National Hospital Ambulatory Medical Care Survey (NHAMCS) over 2007–2018.

Setting US ambulatory (NAMCS) and emergency department (ED, NHAMCS) settings.

Participants Patient visits in which the patient was 18 years and older with an opioid prescription in the NAMCS or NHAMCS databases.

Primary and secondary outcome measures Frequency of opioid plus high-risk medication coprescribing.

Results From a combined sample of 700 499 visits over 2007–2018, there were 105 720 visits (15.1%) where opioids were prescribed. n=31 825 were from NAMCS and n=73 895 were from NHAMCS. The mean prevalence of coprescription of opioids and high-risk medications for the combined NAMCS and NHAMCS sample was 18.4% in 2007, peaked at 33.2% in 2014 and declined to 23.8% in 2018. Compared with adults receiving opioid prescriptions alone, those coprescribed opioids and high-risk medications were older, more likely female, white and using private or Medicare insurance (p<0.0001).

Conclusions Coprescribing is more common in ambulatory than ED settings and has been declining, yet one in four patient visits where opioids were prescribed resulted in coprescribed, high-risk medications in 2016. Efforts and research to help lower the rates of high-risk prescribing are needed.

INTRODUCTION

Opioids are widely prescribed to treat many types of acute and chronic pain, among other diagnoses. In the USA in 2017, there were 58 opioid prescriptions for every 100 persons and one-third (30.7%) of individuals who went to an emergency department (ED) for pain were given or prescribed an opioid. The benefits of opioids, however, are accompanied by significant risks of complications, including overdose: more than 70% of the approximately 71 000 drug overdose deaths in the USA in 2019 involved opioids. In 2019, 40.2% of all suspected drug overdose deaths in the ED were from opioids. Salzman et al used National Hospital Ambulatory Medical Care Survey (NHAMCS) data to show that between 1999 and 2013, the number of opioid-related ED visits increased from 125 000 in 1999 to over 300 000 in 2013. Encouragingly, within the last 5 years (ie, since 2014), opioid prescribing has decreased. Efforts to address the opioid epidemic such as use of prescription drug monitoring programmes and the 2016 Centers for Disease Control and Prevention (CDC) opioid guidelines have contributed to this decline in opioid prescribing.

Although rates of opioid prescribing are declining, rates of overdose and other serious complications remain at epidemic levels. Importantly, rates of synthetic opioid-related (excluding methadone) deaths between 2013 and 2019 increased 1040%.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ Large sample size (n=105 720 in the analytical sample).
⇒ Rigorous sampling methods for National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) create a sample that is representative of US population and, therefore, results can be generalised to generate recommendations.
⇒ NAMCS and NHAMCS count patient visits, not individual patients; therefore, this study is unable to comment on how doses for opioids and/or high-risk drugs have changed over time for individuals.
(prescriptions and illicit sources), non-fatal drug overdoses in EDs increased almost 10.0% between 2016 and 2017 and between 2018 and 2019, and there is emerging evidence that overdoses have increased during the COVID-19 pandemic. This suggests that reducing opioid prescribing alone may not suffice to stem the tide of opioid harms, and thus other targets of intervention should be sought. One major concern with opioid prescribing is coprescription with other medications that put an individual at higher risk for complications (eg, respiratory depression). The coprescription of benzodiazepines with opioids is of particular concern given the up to 10-fold increase in mortality risk when these drugs are taken together.

It is unknown how frequently opioids are coprescribed with benzodiazepines, muscle relaxants, cannabinoids, hypnotics, tricyclic antidepressants and gabapentinoids, all of which are high-risk medications (ie, have an increased, associated risk of respiratory depression) when taken with opioids. Our objective was to evaluate the annual frequencies and trends of these coprescriptions using nationally representative samples of patient visits in the USA over the preceding decade.

METHODS

Data

We used data from the National Ambulatory Medical Care Survey (NAMCS) and NHAMCS, both of which collect cross-sectional data annually regarding the provision and use of medical services in the USA. The NAMCS collects data from office-based healthcare provider visits, and the NHAMCS collects data from hospital EDs and outpatient departments throughout the USA. These data are collected, maintained and distributed annually by the National Center for Health Statistics of the CDC. Both surveys rely on multistage probability sampling to capture a representative sample of provision and access to care among the US population. Physicians and other clinicians are randomly assigned a 1-week (NAMCS) or 4-week (NHAMCS) reporting period in which to capture and convey data. Detailed descriptions of these data sets are well documented and publicly available.

We analysed data from 2007 to the most recently available year of data for NAMCS (2016) and NHAMCS (2018). We included only ED visits from NHAMCS as outpatient visits were categorised as having poor data quality over 2012–2017 and no further data collection over 2018–2020. We examined data from NAMCS and NHAMCS (ie, not just one or the other) in order to provide a more complete description of high-risk coprescribing. Additionally, NAMCS and NHAMCS data structures are compatible to merge and examine in aggregate (hereafter referred to as ‘the combined sample’). We followed the Strengthening the Reporting of Observational Studies in Epidemiology guidelines to report the results from this study.

Data collection, measurement and analyses

Study sample

The analysis for this study was conducted from October 2020 to March 2021. The unit of analysis was the patient visit. Visits in which the patient was 18 years of age or older and had an existing opioid prescription or was newly prescribed an opioid at the point of care were included in the analytical sample. Data that were missing for prescription information or age were excluded from these analyses. We derived opioid prescriptions from the ‘DRUG ID’ variables in the data sets. We compiled and derived a list of opioids using the Ambulatory Care Drug Database System and high-risk coprescriptions were identified using subject matter expertise accompanied by literature review (online supplemental appendix table A).

Outcome

The main outcomes for this analysis were the annual frequencies of opioid plus high-risk medication coprescribing.

Effect modifiers

We examined demographic and clinical variables, such as natal sex, race, ethnicity, age, new versus continuing prescription, region and urbanicity (ie, residency in a metropolitan statistical area (MSA) vs residency not in an MSA). We examined these data separately and in the combined sample.

Other strata

In addition to examining the frequencies of high-risk medications with concurrent opioid prescription, we also examined trends by year and by type of medication. We also compared the demographic characteristics of the sample of visits where an opioid only was prescribed versus visits where an opioid and one or more high-risk medications were prescribed. Lastly, we compared the top five reasons for visits among patient visits with an opioid prescription and high-risk medication, stratified between NAMCS and NHAMCS.

Statistical analysis

We used SAS V.9.4 (SAS Institute) for all analyses and visualisations; for the descriptive statistics, we reported number and percentage (n (%)) or mean and SD (n (SD)), along with 95% CIs for all estimates. We also described demographic differences between adults prescribed an opioid only versus adults prescribed an opioid plus a high-risk medication with frequencies (n (%)), means and SDs (n (SD)) and 95% CIs, in addition to Rao-Scott χ² tests for categorical variables and a t-test for age (the only continuous variable). Using frequentist methodology, we set alpha=0.05 as our statistical threshold for type I error.

Patient and public involvement

It was not possible for the authors of this study to involve the public in the design of this research study, as the data sets (ie, NAMCS and NHAMCS) are publicly available.
data sets that the CDC collects, creates, cleans and then publishes. Prior to their publishing, these data sets are confidential to the CDC. Additionally, the information of individuals who were included in these data sets is deidentified prior to publishing, so subject involvement would not be possible.

With regard to dissemination, we plan to share results and recommendations with public health officials and clinicians at governmental, non-profit, healthcare and academic organisations so that they can use the results to inform actions to increase prescribing safety for the general public.

RESULTS
From a combined sample of 700,499 visits between 2007 and 2018, there were n=105,720 visits (n=31,825 from NAMCS and n=73,895 from NHAMCS) where opioids were prescribed (figure 1). On average, the mean ages (SD) in the combined sample, NAMCS and NHAMCS, respectively, were 47.6 (18.1), 55.1 (16.7) and 44.4 (17.7) years. There were more females represented by patient visits for combined, NAMCS and NHAMCS (57.6%, 57.7% and 50.9%, respectively) and/or Medicare insurance mechanisms (table 1). All patient visits were attended by patients who were living in an MSA (81.2%, 86.3% and 79.0%, respectively) and using private (30.0%, 34.5% and 27.8%, respectively) and/or Medicare (21.1%, 30.0% and 17.4%, respectively) insurance mechanisms. There were statistically significant differences in the age, race/ethnicity and health insurance status of patients between patient visits in NAMCS versus NHAMCS (alpha=0.05) (table 1).

Mean prevalence of coprescription of opioids and high-risk medications for the combined sample was 18.4% in 2007, peaked at 33.2% in 2014 and declined to 23.8% in 2016 (figure 2). A similar time trend was seen in the ambulatory setting. In ambulatory clinics, coprescription of opioids and high-risk medications was 38.2% in 2007, peaking at 50.0% in 2014 and declining to 45.9% in 2016. The ED setting followed a different time pattern; in 2007, the mean prevalence was 13.5%, peaking at 18.6% in 2017 and decreasing to 16.9% as of 2018. Neither the combined sample, the ambulatory setting, nor the ED setting has decreased to levels observed in the mid-2000s.

Coprescription of high-risk medications with concurrent opioid prescription in the combined sample was with benzodiazepines (11.2%), muscle relaxants (10.1%), gabapentinoids (4.4%), hypnotics (2.4%), tricyclic antidepressants (1.2%) and cannabinoids (<0.1%). This ranking is approximately the same by setting—for ambulatory and ED settings, respectively, benzodiazepines (20.2%; 7.3%) had the highest coprevalence, followed by muscle relaxants (15.4%; 7.7%), gabapentinoids (12.6%; 0.9%), hypnotics (6.8%; 0.5%), tricyclic antidepressants (3.7%; 0.2%) and cannabinoids (0.1%; <0.1%) (table 2). In ambulatory settings, there was a higher frequency of continuing prescriptions versus new prescriptions for all extracted high-risk medications (new vs continuing prescriptions are not distinguished in the ED setting). Ambulatory settings also had the highest frequencies of coprescriptions for all high-risk medications when compared with the combined sample and ED. Notably, NAMCS had more than twice the coprevalence of benzodiazepines, more than 12 times the coprevalence of gabapentinoids and hypnotics and approximately 18 times the coprevalence of tricyclic antidepressants compared with NHAMCS.

Compared with patient visits with an opioid prescription only (n=80,699), patient visits characterised by an opioid prescription and high-risk medication (n=25,021) were more likely to be older, female, white and using private and/or Medicare insurance mechanisms (table 3). All results were p<0.0001.

Pain was the most frequent reason documented at patient visits with a coprescription of opioid and high-risk medications in NAMCS and NHAMCS. For NAMCS, the top reason for visits where opioids were prescribed was documented as ‘general visit/medication refill’ (21.9%), followed by musculoskeletal pain (16.3%), postoperative visit (3.4%), unspecified/other pain (2.5%) and headache/pain in head (1.7%); for NHAMCS, the top reason for visits where opioids were prescribed was musculoskeletal pain (37.4%), followed by chest pain (5.8%), abdominal pain (4.1%), headache/pain in head (4.0%) and motor vehicle accident injury (2.8%) (online supplemental appendix table B).

DISCUSSION
In a nationally representative US sample of 105,720 combined ambulatory and ED adult patient visits over 2007–2018, on average, 18.4%–33.2% of patient visits resulting in an opioid prescription also had another high-risk medication prescribed. This mean prevalence was highest in 2014 (33.2%) and while it has declined steadily since, it nonetheless remained high at around 20.0% in 2016. Furthermore, while prevalence of coprescribing...
Table 1  Demographic characteristics of patients with an opioid prescription, NAMCS (2007–2016) and NHAMCS (2007–2018)

|                | NAMCS (n=31825) | 95% CI       | NHAMCS (n=73895) | 95% CI       | Combined (n=105720) | 95% CI       | P value |
|----------------|-----------------|--------------|-----------------|--------------|---------------------|--------------|---------|
| **Sex**        |                 |              |                 |              |                     |              |         |
| Female         | 57.7            | 57.2 to 58.3 | 57.5            | 57.1 to 57.8 | 57.6                | 57.3 to 57.9 | 0.420   |
| Male           | 42.3            | 41.7 to 42.8 | 42.5            | 42.2 to 42.9 | 42.5                | 42.2 to 42.8 |         |
| **Age, mean (SD)** |            |              |                 |              |                     |              | <0.001  |
| Overall        | 55.1 (16.7)     | 54.9 to 55.3 | 44.4 (17.7)     | 44.3 to 44.5 | 47.6 (18.1)         | 47.5 to 47.7 |         |
| **Age (groups)** |            |              |                 |              |                     |              | <0.001  |
| 18–29          | 7.4             | 7.1 to 7.7   | 24.4            | 24.1 to 24.7 | 19.3                | 19.0 to 19.5 |         |
| 30–39          | 11.6            | 11.3 to 12.0 | 20.4            | 20.1 to 20.7 | 17.8                | 17.5 to 18.0 |         |
| 40–49          | 17.7            | 17.3 to 18.1 | 19.3            | 19.0 to 19.5 | 18.8                | 18.5 to 19.0 |         |
| 50–59          | 23.1            | 22.6 to 23.5 | 16.3            | 16.1 to 16.6 | 18.4                | 18.1 to 18.6 |         |
| 60–69          | 19.4            | 18.9 to 19.8 | 9.3             | 9.1 to 9.5   | 12.4                | 12.2 to 12.6 |         |
| 70–79          | 12.9            | 12.6 to 13.3 | 5.7             | 5.5 to 5.8   | 7.9                 | 7.7 to 8.0   |         |
| 80–89          | 6.8             | 6.6 to 7.1   | 3.8             | 3.6 to 3.9   | 4.7                 | 4.6 to 4.8   |         |
| 90+            | 1.1             | 1.0 to 1.2   | 0.9             | 0.8 to 1.0   | 1.0                 | 0.9 to 1.0   |         |
| **Race and ethnicity** |            |              |                 |              |                     |              |         |
| Non-Hispanic Black | 9.3          | 8.9 to 9.6   | 16.0            | 15.7 to 16.3 | 14.0                | 13.8 to 14.2 | <0.001  |
| Non-Hispanic White | 69.4        | 68.9 to 70.0 | 50.9            | 50.5 to 51.3 | 56.5                | 56.2 to 56.8 |         |
| Non-Hispanic ‘Other’ race* | 2.8 | 2.6 to 3.0   | 2.5             | 2.3 to 2.6   | 2.6                 | 2.5 to 2.7   |         |
| Hispanic       | 6.8             | 6.5 to 7.0   | 9.6             | 9.4 to 9.8   | 8.7                 | 8.6 to 8.9   |         |
| Missing        | 11.7            | 11.4 to 12.1 | 21.0            | 20.8 to 21.3 | 18.2                | 18.0 to 18.5 |         |
| **Geographical region** |            |              |                 |              |                     |              |         |
| Missing†       | 66.4            | 65.8 to 66.9 | –               | –            | –                   | 20.0         | 19.7 to 20.2 |         |
| South          | 11.6            | 11.3 to 12.0 | 38.1            | 37.7 to 38.4 | 30.1                | 29.8 to 30.4 |         |
| West           | 9.2             | 8.9 to 9.5   | 22.1            | 21.8 to 22.4 | 18.2                | 18.0 to 18.5 |         |
| Midwest        | 7.7             | 7.4 to 8.0   | 23.5            | 23.2 to 23.8 | 18.7                | 18.5 to 19.0 |         |
| Northeast      | 5.2             | 4.9 to 5.4   | 16.3            | 16.0 to 16.6 | 13.0                | 12.7 to 13.2 |         |
| **Metropolitan statistical area (MSA)** |            |              |                 |              |                     |              |         |
| Yes            | 86.3            | 85.9 to 86.7 | 79.0            | 78.7 to 79.3 | 81.2                | 81.0 to 81.4 |         |
| No             | 13.7            | 13.3 to 14.1 | 11.9            | 11.6 to 12.1 | 12.4                | 12.2 to 12.6 |         |
| Missing‡       | –               | –            | 9.2             | 8.9 to 9.4   | 6.4                 | 6.3 to 6.5   |         |
| **Health insurance** |            |              |                 |              |                     |              | <0.001  |
| Private        | 34.5            | 34.0 to 35.1 | 27.8            | 27.5 to 28.2 | 30.0                | 29.6 to 30.1 |         |
| Medicare       | 30.0            | 29.2 to 30.2 | 17.4            | 17.1 to 17.7 | 21.1                | 20.8 to 21.3 |         |
| Missing        | 17.5            | 17.0 to 17.9 | 16.8            | 16.5 to 17.0 | 17.0                | 16.7 to 17.2 |         |
| Medicaid       | 9.2             | 8.9 to 9.5   | 19.2            | 19.0 to 19.5 | 16.2                | 16.0 to 16.4 |         |
| Self-pay       | 4.9             | 4.7 to 5.2   | 14.0            | 13.8 to 14.3 | 11.3                | 11.1 to 11.5 |         |
| Worker’s compensation | 2.2 | 2.1 to 2.4   | 1.2             | 1.1 to 1.2   | 1.5                 | 1.4 to 1.6   |         |
| Other          | 1.8             | 1.6 to 1.9   | 2.6             | 2.5 to 2.7   | 2.3                 | 2.2 to 2.4   |         |
| No charge (ie, charity care) | 0.3 | 0.2 to 0.4   | 1.0             | 1.0 to 1.1   | 0.8                 | 0.8 to 0.9   |         |

Type of care

Continued
in non-ED settings (ie, NAMCS) seems to have declined since 2014, coprescribing in ED settings (ie, NHAMCS) seems to have stagnated and increased slightly since 2007.

These ED findings are corroborated by recent findings from the National Syndrome Surveillance Program; a 2019 study revealed that nearly 1 in 5 (18.7%) overdoses from benzodiazepines also involved opioids. These findings must also be considered alongside the 1040% increase in illicit, synthetic opioid overdose rate from 2013 to 2019, as it highlights the urgency of understanding opioid (mis)use both inside and outside clinical settings.

We found that in the outpatient setting, there were higher rates of coprescription of the high-risk medications when they were being refilled versus when new medications were being prescribed. This could again be because primary care providers are often responsible for managing patients’ prescriptions over longer periods of time and may not be the initiator of the prescription. Alternatively, this finding may reflect same-prescriber, temporal offset between initiation of the high-risk coprescriptions and subsequent prescriptions.

These findings also suggest that medication reconciliation and electronic medical record (EMR) alerts to potentially risky coprescribing are two promising (and already existing) interventions. In a prospective cohort study of veteran patients, Malte et al found that a medication EMR flag for providers conferred meaningful differences in reducing risky coprescribing of opioids and benzodiazepines. The effects of EMR flags/alerts for providers may be even more potent when multiple high-risk conditions for opioid misuse are present—Malte et al also found that when patients were flagged for older age (ie, 65 years or older) and mental health conditions, such as post-traumatic stress disorder, both risky coprescribing and general opioid prescribing decreased.

We found that mean coprescribing of opioids and high-risk medications is consistently higher in ambulatory care settings compared with the ED. This finding is unsurprising given that primary care providers are often responsible for high-risk prescribing, whether those providers initiated the prescriptions or were refilling them. Additionally, deprescribing medications is difficult especially for primary care providers; this could be a reason for we observed a higher prevalence of continuing versus new prescriptions in NAMCS.

Figure 2  Mean frequency of high-risk coprescription(s) with opioids. Mean frequency of coprescription of opioids with high-risk drugs increased from 2007 to 2014 for all strata; mean frequency decreased from 2014 to 2016 overall and for National Ambulatory Medical Care Survey (NAMCS) and plateaued from 2014 to 2018 for National Hospital Ambulatory Medical Care Survey (NHAMCS). There is a red line through 2012 because data capture changed from paper to electronic collection for both surveys and could have initially inflated results.

Table 1  Continued

| n (%) | NAMCS (n=31,825) 95% CI | NHAMCS (n=73,895) 95% CI | Combined (n=105,720) 95% CI | P value |
|-------|------------------------|--------------------------|-----------------------------|---------|
| Primary care | 42.1 41.5 to 42.6 | – | – | – |
| Medical care | 31.3 30.7 to 31.8 | – | – | – |
| Surgical care | 26.7 26.2 to 27.2 | – | – | – |
| Emergency department | – | 100.0 | 100.0 to 100.0 | – |

*‘Other’ race includes Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander and multiracial.
†Region not collected for NAMCS from 2012 to 2016.
‡MSA not collected for NHAMCS (ED) for 2012.
ED, emergency department; NAMCS, National Ambulatory Medical Care Survey; NHAMCS, National Hospital Ambulatory Medical Care Survey.

Suvada K, et al. BMJ Open 2022;12:e057588. doi:10.1136/bmjopen-2021-057588
to monitor their use of these combined medications. Additionally, since older patients are more likely to have frequent healthcare visits to address health problems than their younger counterparts, the older average age of the patients could be due to more frequent visits. The issue lies in the observed increased likelihood of older adults being prescribed high-risk medications while receiving more frequent healthcare visits.

In our analyses, females were more likely than males to be given opioids alone (57.1% vs 42.9%, respectively) and more likely to have a coprescription of opioids and a high-risk medication (39.0% vs 41.0%, respectively). This finding is consistent with previous studies that have described sex differences in opioid prescribing and chronic pain. Importantly, females have also been shown to use healthcare more than males which could help explain these findings, though ED visits involving opioid-related problems (eg, opioid poisoning, opioid dependence) tend to be by male patients.

Patient visits characterised by an opioid prescription and a high-risk medication (n=25 021) were more likely to be older, female, white and using private and/or Medicare insurance mechanisms compared with patient visits with an opioid prescription only (n=80 699). There are two additional disparities worth discussing.

First, visits where race was marked ‘Non-Hispanic White’ made up a larger proportion of visits with opioids plus high-risk medications than visits with opioids alone. This is consistent with findings from other studies. One possible explanation for this difference is the medicalisation of drug use in the white population specifically. It is also possible that the lower proportion of coprescriptions with high-risk medications for Black patients is indicative of a resistance among practitioners to treat symptoms out of unfounded concerns of drug misuse. Indeed, the undertreatment of pain in Black patients is well documented.

Second, Medicare visits included a smaller proportion of visits involving opioids only (19.8%) compared with visits involving opioids plus a high-risk drug (25.4%). This finding could be due to the fact that the Medicare population is older than those using Medicaid or private insurance. Our other findings from this study show that visits with older adults more frequently had an opioid and a high-risk medication. Medicare Part D (2006) might also explain our observation, as Medicare became the largest payor for opioid prescriptions after implementation. There is also literature to support higher rates of this type of coprescribing among those with public insurance compared with private insurance or no insurance.

Understanding the reasons for age, race and insurance differences among patients who are coprescribed an opioid and high-risk medication requires further investigation, as do interventions to reduce coprescribing risk. Provider-level interventions currently in practice include education about ways to reduce high-risk prescribing and EMR flags to signal a high-risk prescribing situation.

A key strength of our study included the large sample size of our study population and rigorous sampling methods (eg, sampling weights, multistage probability sampling) for NAMCS and NHAMCS. These lead us to believe that the study population (ie, NAMCS and NHAMCS visits) and source population (ie, total number of ambulatory and ED visits in the USA) are demographically, clinically and geographically representative of care received by Americans.

There are also limitations to this work. First, NAMCS and NHAMCS transitioned from paper to electronic records in 2012, which may have affected how patient data were recorded and could have influenced results. Additionally, these data sets count patient visits, not individual patients, so individuals could be counted more than once, and we cannot parse out the risk of patients receiving prescriptions from multiple clinicians. The most recent NAMCS data available were in 2016 and it is unclear whether and how prescribing practices may have changed since that time, especially given there has been a heightened awareness of the risks of opioid prescribing in recent years. This study is also unable to comment on how doses, days of supply, illicit versus prescription use of, and/or indications of opioids and/or high-risk drugs have changed over time for individual patients. This is particularly important to note in combination with the aforementioned limitation of the data sets only reporting

### Table 2: New and continuing opioid coprescriptions, NAMCS (2007–2016), NHAMCS (2007–2018) and combined sample

| Coprescriptions (%) | NAMCS (N=31 825) Combined (n=18 631) 95% CI | Continuing (n=9 002) 95% CI | New (n=13 194) 95% CI | NHAMCS (N=73 895)* | Combined (N=105 720) Overall 95% CI |
|---------------------|---------------------------------------------|---------------------------|-------------------------|---------------------|-------------------------------------|
| Gabapentinoids      | 12.6 (12.2 to 12.9)                         | 13.6 (13.2 to 14.0)       | 10.3 (9.8 to 10.8)      | 0.9 (0.8 to 1.0)     | 0.9 (0.8 to 1.0)                   |
| Muscle relaxants    | 15.4 (15.1 to 15.8)                         | 15.6 (15.2 to 16.1)       | 15.2 (14.8 to 15.6)     | 7.7 (7.5 to 7.9)     | 7.7 (7.5 to 7.9)                   |
| Benzodiazepines     | 20.2 (19.8 to 20.6)                         | 21.4 (21.0 to 22.0)       | 18.6 (18.2 to 19.2)     | 7.3 (7.1 to 7.5)     | 7.1 (7.0 to 7.3)                   |
| Hypnotics           | 6.8 (6.5 to 7.1)                            | 7.5 (7.2 to 7.9)          | 5.8 (5.4 to 6.2)        | 0.5 (0.4 to 0.6)     | 0.4 (0.3 to 0.5)                   |
| Tricyclic antidepressants | 3.7 (3.5 to 3.9)          | 3.9 (3.7 to 4.2)          | 3.3 (3.0 to 3.6)        | 0.2 (0.2 to 0.3)     | 0.2 (0.2 to 0.3)                   |
| Cannabinoids        | 0.1 (0.1 to 0.2)                            | 0.1 (0.1 to 0.2)          | 0.1 (0.1 to 0.2)        | <0.1 (0.0 to 0.1)    | 0.0 (0.0 to 0.1)                   |

*NHAMCS did/does not distinguish between new and continuing prescriptions.

NAMCS, National Ambulatory Medical Care Survey; NHAMCS, National Hospital Ambulatory Medical Care Survey.
visits, not patients; a patient weaning off of an opioid, for example, will likely be seeing practitioners frequently and will be receiving new prescriptions (tapering doses) frequently, and these data sets could capture this patient multiple times with opioid prescriptions at each visit.59 63 Likely more frequently, though, patient visits with the same patient receiving the same opioid prescription month after month are captured in the data. Lastly, study findings have limited generalisability outside of contexts in the USA.

CONCLUSIONS
US adult medical visits have featured the coprescription of opioids and high-risk medications at a proportion higher than 15% over the last two decades. This is

Table 3  Opioid prescription only versus opioid prescription+high-risk medication for selected demographic variables, combined sample (n=105 720)

| n (%) | Opioid prescription only (n=80 699) | 95% CI | Opioid prescription+high-risk medication (n=25 021) | 95% CI | P value |
|-------|-----------------------------------|--------|-----------------------------------------------|--------|--------|
| Sex   |                                   |        |                                               |        |        |
| Female| 46 067 (57.1)                     | 56.7 to 57.4 | 14 772 (59.0)                             | 58.4 to 59.7 | <0.0001 |
| Male  | 34 632 (42.9)                     | 42.6 to 43.3 | 10 249 (41.0)                               | 40.4 to 41.6 |        |
| Age, mean (SD) |         |        |                                               |        |        |
| Overall| 46.6 (18.4)                       | 46.5 to 46.8 | 50.87 (16.6)                               | 50.7 to 51.1 | <0.0001 |
| Age (groups) |                         |        |                                               |        |        |
| 18–29 | 17 576 (21.8)                     | 21.5 to 22.1 | 2784 (11.1)                                | 10.7 to 11.5 | <0.0001 |
| 30–39 | 14 803 (18.3)                     | 18.1 to 18.6 | 3971 (15.9)                                | 15.4 to 16.3 |        |
| 40–49 | 14 790 (18.3)                     | 18.1 to 18.6 | 5059 (20.2)                                | 19.7 to 20.7 |        |
| 50–59 | 13 735 (17.0)                     | 16.7 to 17.3 | 5668 (22.7)                                | 22.1 to 23.2 |        |
| 60–69 | 9094 (11.3)                       | 11.1 to 11.5 | 3963 (15.8)                                | 15.4 to 16.3 |        |
| 70–79 | 6035 (7.5)                        | 7.3 to 7.7  | 2262 (8.0)                                 | 8.7 to 9.4  |        |
| 80–89 | 3826 (4.7)                        | 4.6 to 4.9  | 1136 (4.5)                                 | 4.3 to 4.8  |        |
| 90+   | 840 (1.0)                         | 1.0 to 1.1  | 178 (0.7)                                  | 0.6 to 0.8  |        |
| Race and ethnicity |             |        |                                               |        |        |
| Non-Hispanic Black | 14.7 | 14.4 to 14.9 | 11.7 | 11.3 to 12.1 | <0.0001 |
| Non-Hispanic White  | 53.9 | 53.6 to 54.3 | 64.8 | 64.2 to 65.4 |        |
| Non-Hispanic ‘Other’ race* | 2.7 | 2.6 to 2.8 | 2.2 | 2.0 to 2.3 |        |
| Hispanic | 9.2 | 9.0 to 9.4 | 7.3 | 7.0 to 7.6 |        |
| Missing | 19.5 | 19.3 to 19.8 | 14.0 | 13.6 to 14.5 |        |
| Geographical region |             |        |                                               |        |        |
| South  | 25 708 (31.9)                     | 31.5 to 32.2 | 6114 (24.4)                                | 23.9 to 25.0 | <0.0001 |
| Midwest | 16 259 (20.2)                     | 19.9 to 20.4 | 3556 (14.2)                                | 13.8 to 14.6 |        |
| West   | 13 814 (19.6)                     | 19.3 to 19.9 | 3466 (13.9)                                | 13.4 to 14.3 |        |
| Missing† | 11 467 (14.2)                     | 14.0 to 14.5 | 9652 (38.6)                                | 38.0 to 39.2 |        |
| Northeast | 11 451 (14.2)                     | 14.0 to 14.4 | 2233 (8.9)                                 | 8.6 to 9.3  |        |
| Health insurance |             |        |                                               |        |        |
| Private | 23 792 (29.5)                     | 29.2 to 29.8 | 7769 (31.1)                                | 30.5 to 31.6 | <0.0001 |
| Medicare | 15 945 (19.8)                     | 19.5 to 20.0 | 6346 (25.4)                                | 24.8 to 25.9 |        |
| Missing | 13 815 (17.1)                     | 16.9 to 17.4 | 4119 (16.5)                                | 16.0 to 17.0 |        |
| Medicaid | 13 831 (16.9)                     | 16.6 to 17.2 | 3508 (14.0)                                | 13.6 to 14.5 |        |
| Self-pay | 9767 (12.1)                      | 11.9 to 12.3 | 2150 (8.6)                                 | 8.3 to 9.0  |        |
| Other  | 1911 (2.4)                        | 2.3 to 2.5  | 550 (2.2)                                  | 2.0 to 2.4  |        |
| Worker’s compensation | 1115 (1.4) | 1.3 to 1.5 | 452 (1.8) | 1.6 to 2.0 |        |
| No charge (ie, charity care) | 723 (0.9) | 0.8 to 1.0 | 127 (0.5) | 0.4 to 0.6 |        |

*‘Other’ race includes Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander and multiracial.
†Region not collected for National Ambulatory Medical Care Survey (NAMCS) from 2012 to 2016.
concerning. This study advances the current state of knowledge in understanding risky prescribing situations involving opioids by identifying key settings (ie, outpatient clinics), contexts (ie, prescription refills/continuations) and demographic groups (ie, older females), in which these situations are occurring. Trends should continue to be studied and updated with newly released data to assess whether ongoing interventions and efforts to reduce high-risk coprescribing are effective. New and existing targeted and evidence-based interventions should be implemented and then evaluated to improve patient safety and reduce excess coprescribing.

Author affiliations
1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
2School of Medicine, Emory University, Atlanta, Georgia, USA
3Division of Palliative Medicine, Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA
4Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
5Department of Family and Preventive Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA

Twitter Kara Suvada @k_suvada

Acknowledgements KS thanks MKA for his mentorship in this study. The entire study team also thanks the members of Emory's Injury Prevention Research Center and members of Emory School of Medicine's Department of Family and Preventive Medicine for consistent feedback on the relevance and scope of this project.

Contributors KS conducted the data analysis, contributed to manuscript writing, organised study meetings, conceptualised study design and prepared the manuscript for submission. AZ constructed the study tables, contributed to manuscript writing and contributed to subject matter expertise. MKA provided study and clinical oversight, contributed to manuscript writing and helped conceptualise the study design. JS, JSM and DK provided critical feedback on manuscript drafts, and clinical and health services subject matter expertise. KS obtained the data for this study from publicly available NAMCS and NHAMCS data sets provided by the CDC and NCHS. KS is the guarantor of this work and accepts full responsibility for the study.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests DK receives research and programmatic funding from the Cystic Fibrosis Foundation, the Fraser-Parker Foundation and the National Heart, Lung and Blood Institute (K01HL133466). MKA receives a grant (to Emory University) from Merck & Co.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval This study was exempt from review by the Emory University IRB because NAMCS and NHAMCS are publicly available data sets that contain no patient identifiers.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. We used data from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS), both of which collect cross-sectional data annually regarding the provision and use of medical services in the USA. These data are collected, maintained and distributed annually by the National Center for Health Statistics of the Centers for Disease Control and Prevention. Detailed descriptions of these data sets are well documented and publicly available.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Kara Suvada http://orcid.org/0000-0003-2785-835X

REFERENCES
1 Sherry TB, Sabetty A, Maestas N. Documented pain diagnoses in adults prescribed opioids: results from the National ambulatory medical care survey, 2006-2013. Ann Intern Med 2015;163:498-505.
2 CDC. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes - United States. Atlanta, GA Centers for Disease Control and Prevention; 2018.
3 Schappert S, Santo L. QuickStats: Percentage of Emergency Department Visits for Pain at Which Opioids Were Given or Prescribed, by Geographic Region § of the Hospital - United States, 2005-2017. MMWR 2020;69:93.
4 Centers for Disease Control and Prevention. Drug overdose deaths, opioid overdose, 2020. Available: https://www.cdc.gov/drugoverdose/data/statedeaths.html [Accessed 21 Sep 2020].
5 Liu S, Scholl L, Hoots B, et al. Nonfatal Drug and Polydrug Overdoses Treated in Emergency Departments - 29 States, 2018-2019. MMWR Morb Mortal Wkly Rep 2020;69:1139-45.
6 Saltzman M, Jones CW, Rafiq R, et al. Epidemiology of opioid-related visits to US emergency departments, 1999-2013: a retrospective study from the NHAMCS (National Hospital ambulatory medical care survey). Am J Emerg Med 2020;38:23-7.
7 Centers for Disease Control and Prevention. U.S. Department of Health and Human Services. Annual Surveillance Report of Drug-Related Risks and Outcomes - United States; 2018: 31.
8 Strickler GK, Kreiner PW, Halpin JF, et al. Opioid Prescribing Behaviors – Prescription Behavior Surveillance System, 11 States, 2010-2016. MMWR Surveill Summ 2020;69:1-14.
9 Suffoletto B, Lynch M, Pacella CB, et al. The effect of a statewide mandatory prescription drug monitoring program on opioid prescribing by emergency medicine providers across 15 hospitals in a single health system. J Pain 2019;18:430-6.
10 Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep 2016;65:1-49.
11 Hwang CS, Chang H-Y, Alexander QC. Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoeconomic Drug Saf 2012;11:197-204.
12 Dowell D, Zhang K, Noonan RK, et al. Mandated provider review and pain clinic laws reduce the amounts of opioids prescribed and overdose death rates. Health Aff 2016;35:1876-83.
13 Mattson CL, Tanz LJ, Quinn K, et al. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep 2021;70:202-7.
14 Vivolo-Kantor AM, Hoots BE, Scholl L, et al. Nonfatal Drug Overdoses Treated in Emergency Departments - United States, 2016-2017. MMWR Morb Mortal Wkly Rep 2020;69:371-6.
15 Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts National Center for Health Statistics; 2021.
16 Algira MH, Kamp J, van der Schrier R, et al. Opioid-Induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. Br J Anaeth 2019;122:168-79.
17 Xu KY, Hartz SM, Borodovsky JT, et al. Association between benzodiazepine use with or without opioid use and all-cause mortality in the United States, 1999-2015. JAMA Netw Open 2020;3:e2002657.
18 Koffel E, DeRonne B, Hawkins EJ. Co-Prescribing of opioids with benzodiazepines and other hypnotics for chronic pain and insomnia: trends and health outcomes. Pain Med 2020;21:2055-9.
19Dasgupta N, Funk MJ, Proescholdbell S, et al. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med 2016;17:85-98.
20 Li Y, Delcher C, Wei Y-JJ, et al. Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants: a population-based cohort study. *Clin Pharmacol Ther* 2020;108:81–9.
21 Cho J, Spence MM, Niu F, et al. Risk of overdose with exposure to prescription opioids, benzodiazepines, and non-benzodiazepine Sedative-Hypnotics in adults: a retrospective cohort study. *J Gen Intern Med* 2020;35:696–703.
22 Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. *Life Sci* 2004;74:1317–24.
23 National Institute on Drug Abuse. Benzodiazepines and opioids, 2021. Available: https://www.drugabuse.gov/drug-topics/opioids/benzodiazepines-opioids [Accessed 12 Mar 2021].
24 Bykov K, Bateman BT, Franklin JM, et al. Association of Gabapentinoids with the risk of Opioid-Related adverse events in surgical patients in the United States. *JAMA Netw Open* 2020;3:e2013647.
25 Chan GM, Stajic M, Marker EK, et al. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. *Acad Emerg Med* 2008;15:542–7.
26 Centers for Disease Control and Prevention. Ambulatory health care data. datasets and documentation, 2020. Available: https://www.cdc.gov/nchs/ahcd/datasets_documentation_related.htm [Accessed 12 Mar 2021].
27 Centers for Disease Control and Prevention. National center for health statistics: notices for NAMCS and NHAMCS public use data file users, 2019. Available: https://www.cdc.gov/nchs/ahcd/notice.htm [Accessed 12 Mar 2021].
28 von Eim E, Altman DG, Eger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007;147:573–7.
29 Centers for Disease Control and Prevention. The ambulatory care drug database, 2018. Available: https://www2.cdc.gov/drugs/applicationnav1.asp [Accessed 12 Mar 2021].
30 Mason M, Welch SB, Arunkumar P, et al. Notes from the Field: Opioid Overdose Deaths Before, During, and After an 11-Week COVID-19 Stay-at-Home Order - Cook County, Illinois, January 1, 2018-October 6, 2020. *MMWR Mort Mort Wkly Rep* 2021;70:362–3.
31 Tong ST, Hochheimer CJ, Brooks EM, et al. Chronic opioid prescribing in primary care: factors and perspectives. *Ann Fam Med* 2019;17:200–6.
32 Levy B, Paulozzi L, Mack KA, et al. Trends in opioid Analgesic-Prescribing rates by specialty, U.S., 2007-2012. *Am J Prev Med* 2015;49:409–13.
33 Malte CA, Berger D, Saxon AJ, et al. Electronic medical record alert associated with reduced opioid and benzodiazepine Coprescribing in high-risk veteran patients. *Med Care* 2018;56:171–8.
34 Dreischulte T, Guthrie B. High-Risk prescribing and monitoring in primary care: how common is it, and how can it be improved? *Ther Adv Drug Saf* 2012;3:175–84.
35 Garg RK, Fulton-Kehoe D, Franklin GM. Patterns of opioid use and risk of opioid overdose death among Medicaid patients. *Med Care* 2017;55:681–8.
36 Jeffery MM, Hooten WM, Jena AB, et al. Rates of physician Coprescribing of opioids and benzodiazepines after the release of the centers for disease control and prevention guidelines in 2016. *JAMA Netw Open* 2019;2:e198325.
37 Prunuske JP, St Hill CA, Hager KD, et al. Opioid prescribing patterns for non-malignant chronic pain for rural versus non-rural US adults: a population-based study using 2010 NAMCS data. *BMC Health Serv Res* 2014;14:563.
38 Bertakis KD, Azari R, Helms LJ, et al. Gender differences in the utilization of health care services. *J Fam Pract* 2000;49:147–52.
39 POT R. National ambulatory medical care survey: 2016 national summary tables.
40 P KJ R. National Hospital ambulatory medical care survey: 2017 emergency department summary tables. National Center for Health Statistics.
41 Barnsteiner J, Reconciliation M. Medicine Reconciliation. In: Hughes RR, ed. *Patient safety and quality: an evidence-based Handbook for nurses, Rockville, MD: Agency for Healthcare Research and Quality (US), 2008.
42 Gudin JA, Mogali S, Jones JD, et al. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. *Postgrad Med* 2013;125:115–30.
43 Hirschtritt ME, Delucchi KL, Olsson M. Outpatient, combined use of opioid and benzodiazepine medications in the United States, 1993-2014. *Prev Med Rep* 2018;9:49–54.
44 Netherland J, Hansen H. White opioids: Pharmaceutical race and the war on other drugs. *JAMA Intern Med* 2017;177:1217–18.
45 By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American geriatrics Society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2019;67:4–94.
46 Hausmann RM, GJ, S, Lee ES, et al. Racial disparities in the monitoring of patients on chronic opioid therapy. *Pain* 2013;154:46–52.
47 Pearson S-A, Soumerai S, Mah C, et al. Racial disparities in access after regulatory surveillance of benzodiazepines. *Arch Intern Med* 2006;166:572–9.
48 Mezghani SH, Byun E, Gallagher RM. Time to take stock: a meta-analysis and systematic review of analytic treatment disparities for pain in the United States. *Pain Med* 2012;13:150–74.
49 Akinlade O. Taking black pain seriously. *J Ethnol Med* 2020;383:e68.
50 Cooper LA, Roter DL, Carson KA, et al. The associations of clinicians’ implicit attitudes about race with medical visit communication and patient ratings of interpersonal care. *Am J Public Health* 2012;102:979–87.
51 MedPac. A data book: health care spending and the Medicare program; 2019: 21–5.
52 Center for Medicaid and CHIP Services. Medicaid & CHIP Beneficiaries at a Glance. In: Outcomes DoQah 2020:1–2.
53 Samuel L, Miller-McClain K, Lind K. Fact sheet: who relies on Medicaid? A profile of the Medicare population. AARP Public Policy Institute 2017:836.
54 Zhou C, Florence CS, Dowell D. Payments for opioids shifted substantially to public and private insurers while consumer spending increased. *JAMA* 2017;318:2040–4.
55 Tardelli VS, Fidalgo TM, Santaela J, et al. Medical use, non-medical use and use disorders of benzodiazepines and prescription opioids in adults: differences by insurance status. *Drug Alcohol Depend* 2019;204:107573.
56 Cochella S, Bateman K. Provider detailing: an intervention to decrease prescription opioid deaths in Utah. *Pain Med* 2011;12 Suppl 2:S73–6.
57 Seymour RB, Leas D, Wally MK, et al. Prescription reporting with immediate medication utilization mapping (primum): development of an alert to improve narcotic prescribing. *JAMA Netw Open* 2019;2:e20027481.
58 Scherrer JF, Tucker J, Salas J, et al. Comparison of opioids prescribed for patients at risk for opioid misuse before and after publication of the centers for disease control and prevention’s opioid prescribing guidelines. *JAMA Netw Open* 2020;3:e200736.
59 Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. *Ann Intern Med* 2017;167:181–91.
60 Montoya JC, Coricai Z, Herring AA, et al. Association of default electronic medical record settings with health care professional patterns of opioid prescribing in emergency departments: a randomized quality improvement study. *JAMA Intern Med* 2020;180:487–93.
61 Smalley CM, Willner MA, MuiR MR, et al. Electronic medical record-based interventions to encourage opioid prescribing best practices in the emergency department. *Am J Emerg Med* 2020;38:1647–51.
62 Hwang MI, Bond WF, Powell ES. Sepsis alerts in emergency departments: a systematic review of accuracy and quality measure impact. *West J Emerg Med* 2020;21:1201–10.
63 Heins SE, Sorbero MJ, Jones CM, et al. High-Risk prescribing to Medicaid enrollees receiving opioid analgesics: Individual- and County-Level factors. *Subst Use Misuse* 2018;53:1591–601.